Blueprint Medicines (NASDAQ:BPMC) Upgraded to “Outperform” at Oppenheimer
Oppenheimer upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a market perform rating to an outperform rating in a report issued on Friday, MarketBeat.com reports. The brokerage currently has $85.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on BPMC. StockNews.com initiated coverage on shares of […]
More Stories
Corning Natural Gas (OTCMKTS:CNIG) vs. Centuri (NYSE:CTRI) Financial Comparison
Centuri (NYSE:CTRI – Get Free Report) and Corning Natural Gas (OTCMKTS:CNIG – Get Free Report) are both utilities companies, but...
Critical Analysis: Lucas GC (NASDAQ:LGCL) versus Sangoma Technologies (NASDAQ:SANG)
Institutional & Insider Ownership 39.7% of Sangoma Technologies shares are owned by institutional investors. 14.0% of Sangoma Technologies shares are...
Americans Need $5.3 Million Net Worth to Be Considered Financially Successful: Survey
By Naveen Athrappully Americans have high expectations of what it means to be financially successful but many of them do...
2 Key Congressional Races Still Uncalled in California
By Kimberly Hayek Republicans have secured a trifecta in the November general election, taking control of the Oval Office, House,...
Hyundai Recalls 145,000 Hybrids Over Potential Battery Charging Issue
By Wim De Gent South Korean automaker Hyundai is recalling over 145,000 hybrid electric vehicles in the United States over...
Inositol: A Sugar That Stabilizes Mood and Hormones–Here’s How to Get It
By Sina McCullough Inositol is a type of sugar found naturally in fruits, beans, grains, and nuts. While sugar is...